BioTuesdays

Tag - CBMG

Cellular Biomedicine Group

TBIG starts Cellular Biomedicine at buy; PT $19

TBIG launched coverage of Cellular Biomedicine Group (NASDAQ:CBMG) with a “buy” rating and $19 price target. The stock closed at $14.84 on Sept. 16. Cellular has been developing its cGMP grade cell therapy manufacturing...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.